Payment overview · 2025
General Payments
$106.18
5 reported records · 3 companies
Healthcare provider profile · identity verified
Kelly Roden, MD
Allopathic & Osteopathic Physicians|Family Medicine · TYLER, TX · NPI 1730538513
Verified facts
What the public records show
CMS Open Payments records show Kelly Roden, MD received $106.18 in general payments during 2025 across 5 reported records.
Corcept Therapeutics accounted for 64.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $68.67 | 64.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.69 | 22.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.82 | 13.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.18 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $68.67 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 342 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 280 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 58 |
| Potassium Chloride | Potassium Chloride | 243 | 46 |
| Furosemide | Furosemide | 228 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 56 |
| Gabapentin | Gabapentin | 210 | 54 |
| Lisinopril | Lisinopril | 210 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 50 |
| Sertraline Hcl | Sertraline Hcl | 160 | 28 |
| Tramadol Hcl | Tramadol Hcl | 155 | 30 |
| Eliquis | Apixaban | 144 | 13 |
| Alprazolam | Alprazolam | 136 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 34 |
| Meloxicam | Meloxicam | 132 | 28 |
| Losartan Potassium | Losartan Potassium | 129 | 26 |
| Trazodone Hcl | Trazodone Hcl | 114 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 22 |
| Buspirone Hcl | Buspirone Hcl | 109 | 15 |
| Metformin Hcl | Metformin Hcl | 107 | 26 |
| Clonazepam | Clonazepam | 102 | 16 |
| Omeprazole | Omeprazole | 100 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 94 | 18 |
| Donepezil Hcl | Donepezil Hcl | 89 | 13 |
| Cephalexin | Cephalexin | 86 | 51 |
| Carvedilol | Carvedilol | 85 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 20 |
| Azithromycin | Azithromycin | 72 | 61 |
| Ozempic | Semaglutide | 68 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | suppressed |
| Simvastatin | Simvastatin | 65 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 13 |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Famotidine | Famotidine | 55 | 12 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Allopurinol | Allopurinol | 48 | 14 |
| Prednisone | Prednisone | 48 | 33 |
| Celecoxib | Celecoxib | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Estradiol | Estradiol | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 15 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 13 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Lorazepam | Lorazepam | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.18 · 5 records | Corcept Therapeutics | Cologuard Collection Kit, Korlym, TZIELD | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with SANOFI-AVENTIS U.S. LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error